TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: patient comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Related Discontinuations
Endpoint domain: Adverse events/effects
Primary endpoint: Achilles tendon cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sound Quality Ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delay in days between endoscopic biliary drainage and chemotherapy treatment start
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of valvular heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Metabolic control level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pain at cough after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative rescue analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Neural activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correlation between ctDNA mutations and recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline in the mean GSAS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean GSAS score in children with CF on GERD therapy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ScO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in language and executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive executive function assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in visuospatial memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent positive tumour cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of brolucizumab injections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Deep Neck Core Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary advanced glycation end products intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Comparison of measurements from J-bar fiducial and staple line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Collection of occurrence of IMP-related SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in the results of serum biochemistry test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of blood pressure in mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal tolerated dose (MTD) of EGFRt/19-28z/IL-12 chimeric antigen receptor T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in vital signs: Blood pressure (Systolic/Diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of subjects with complete cure of the target toenail
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Handgrip strength measurement in kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity in depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BOLD signal amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG signal amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcome of Distal Penile Hypospadias Repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capability of vascular monitoring device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptability of ID probe blood flow monitoring device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Manganese Uptake (Ki)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adjuvant chemotherapy completion rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: IL-6 levels in tooth exudate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mindfulness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drexel Cognitive Defusion Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Students' Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median Pressure reached by non-invasive ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment Discontinuations due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Kujala score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quantification of endocrine disruptors in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Parenting Sense of Competence Scale: Efficacy Subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modified Differential Emotions Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Radioactive uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manifestations of lesions on MR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal characteristics on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of vaccine-matched IgG binding Ab responses as assessed by multiplex assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median SOFA score increase >2 points on day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median respiratory support-free days increase at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects surviving/dying day 28
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac Symptom Distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in muscle oxygenation kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ESKAPE transmission events
Endpoint domain: Adverse events/effects
Primary endpoint: 2-fold growth rate of IgG antibodies to 23 pneumococcal serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean concentration (GMC) of IgG antibodies to 23 pneumococcal serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of serious adverse events (SAE) within 6 months after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: decrease of semen parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: in-hospital bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of MK-1167 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in health care acquired neonatal infection
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of liver function tests (ALT and AST levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First-pass success rate of videolaryngoscopic intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of AI based model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 doses (RP2D) of XNW5004 in combination with enzalutamide
Endpoint domain: Resource use
Primary endpoint: Preliminary efficacy determination as evaluated by disease specific response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of COVID-19-related critical illness or all-cause death within 28 days
Endpoint domain: Mortality/survival
Primary endpoint: LFPs recordings from the STN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Device deficiencies
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Peri-procedural adverse device effects for each investigational device type
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Post-procedural adverse device effects
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Clinical benefit confirmations per number of use cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diaphragm thickening fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: dEMG amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dEMG tonic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Control at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fallopian tube recanalization (patency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sensitivity and specificity of the blood test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Occupational Self-Efficacy (5 weeks post intervention)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Occupational Self-Efficacy (19 weeks post intervention)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Attitudes towards addressing sexuality (5 weeks post intervention)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Attitudes towards addressing sexuality (19 weeks post intervention)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Volume changes of the vestibular gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear dimensional changes of the vestibular gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Activation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family Empowerment
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mean change in EPSS measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Caries Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcomes Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Perception of Dyspnea questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Quality of Life about respiratory disease questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from disability questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in portal and arterial hepatic blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in portal vein and caval vein pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Early rebleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life measured by Short Form-36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disability measured by Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants with GD relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events observed after single or multiple doses
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory abnormalities following single or multiple ascending doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital sign changes following single or multiple ascending doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of text message sessions successfully delivered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pregnancy related low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number and percentage of patients with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse event events as assessed by CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Task switching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working memory (N-back)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Processing speed (Simple reaction time task)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success/failure of common bile duct removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in Absorption of Wet Weight/Fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single protein changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in tumor-specific immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Skin thickness ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ex vivo DCFDA test on red blood cells (RBCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma lipid peroxydes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Methemoglobin in red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nitrosylated hemoglobin (HbNO) in red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Satisfaction Rate of Stent Expansion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients with a negative provocation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of morphine equivalents per kilogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for mechanical ventilation at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tibiofemoral articular cartilage's glycosaminoglycan content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibiofemoral articular cartilage thickness (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibiofemoral joint space narrowing (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of participants achieving any hematologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of Relapse after prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parents' quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adherence to prescribed therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic accuracy of MC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cmax of ramipril and ramiprilat in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-72 of ramipril and ramiprilat in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient reported outcomes of spasticity on NRS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in clinical passive range of motion at the elbow joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac device infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients demonstrating dose limiting toxicities and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients exhibiting reduction in tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ISC Scores validation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Tolerance Dose (MTD) or recommended phase II dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: NTproBNP measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time of first rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood oxygen saturation level (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Objective assessment of ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Any adverse effects related to treatment modality
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Evaluation of Middle Ear Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular uncorrected visual acuities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight of children with IEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Height of children with IEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass index for age (BMI for age)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reaction time in the spatial 2-, 3-, 4-back
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: d prime in the spatial 2-, 3-, 4-back
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in BASDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adhesion to guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: days needed for first bowel motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Primary assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum concentrations of neurofilament light chains (NfL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: perioperative opioids consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Death Preparation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: End-of-Life Care Preferences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measure of non-inflammatory nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of self-reported improvement in HS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measure of pain/itch level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants Who Received 3 or More Cycles of the Combination of Entinostat, Atezolizumab, Carboplatin, and Etoposide
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Attitudes and beliefs toward people with mental disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stigmatizing attitudes towards people with mental health disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acquired knowledge in students
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy of indirectly placed brackets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecal Calprotectin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: C-reactive Protein (CRP) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte Sedimentation Rate (ESR) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in shoulder strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Functional outcome according to the American Shoulder and Elbow Surgeons (ASES) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional outcome according to the Constant-Murley score (CMS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning